JAK2 and myeloproliferative disorder: A kinase domain-focused CRISPR screen previously highlighted that two JAK2 mutant BP-MPN cell lines (human erytholeukemia (HEL) and the megakaryoblastic leukemia line (SET2)) are hypersensitive to DYRK1A targeting compared with other AML cell lines35.